Atomos generated positive operating cash flow of A$0.9 million in Q1 FY27, although quarterly sales fell to A$9.2 million and cash remained modest against A$21.1 million of borrowings. The company is relying on seasonal strength, Shinobi 7 II demand and new Flanders Scientific products to lift the December quarter.
- A$0.9 million positive operating cash flow in Q1 FY27
- Sales declined to A$9.2 million from A$10.5 million a year earlier
- Shinobi 7 II demand is being constrained by component shortages
- Cash of A$2.0 million compared with A$21.1 million of borrowings
- Q2 launch program and seasonal demand expected to support trading
Positive cash flow masks a softer sales quarter
Atomos Limited (ASX:AMS) has returned to positive operating cash flow, but the quarter also exposed the delicate arithmetic of its recovery. The video technology group generated A$0.9 million from operations in Q1 FY27, while sales fell to A$9.2 million from A$10.5 million a year earlier and A$9.7 million in the previous quarter.
The cash result was helped by A$10.8 million of customer receipts as Atomos collected an elevated debtor balance carried over from 30 June. That makes the inflow useful, but not a clean measure of underlying sales momentum. Fixed costs remained under control, according to the company, while A$0.8 million of investing cash outflow was mainly directed to capitalised development and intellectual property.
Shinobi demand runs into component shortages
Demand for Shinobi II and the recently released Sumo PRO 19 supported the quarter, with Flanders Scientific contributing in line with expectations. Shinobi 7 II began shipping in late September and has further orders in backlog, but Atomos said industry-wide component shortages are constraining inventory and that production is being prioritised to meet orders.
The new monitor is a 7-inch, 2,800-nit HDR product with camera control, priced at US$499. Atomos and Flanders also used IBC 2026 in Amsterdam to present a connected workflow spanning on-camera monitoring, on-set production and finishing. The pair collected three awards, including two for Shinobi 7 II and one for Flanders’ GaiaColor AutoCal and Analyzer products.
Flanders broadens the product pipeline
Flanders Scientific is now contributing its first full quarter to the group after the Flanders Scientific acquisition was funded through a new Commonwealth Bank facility. Atomos has launched a combined product catalogue and expects new Flanders reference monitors during Q2, alongside the Shogun AV-19M broadcast monitor-recorder and further software integrations.
The portfolio expansion is arriving alongside a reshaped route to market. Atomos said it is moving towards direct relationships with key European resellers and adding distribution partners in Australia, Japan and India. Whether those changes convert product interest into repeatable revenue remains a more important test than the awards themselves.
Cash remains thin against substantial borrowings
At 30 September, Atomos held A$2.0 million in cash and cash equivalents against A$21.1 million of borrowings. The debt comprises a A$10.0 million Commonwealth Bank facility and a Monreii loan liability of A$11.1 million, including capitalised interest. The Monreii facility matures in February 2028 and carries a stated cost of 13%, while the CBA facility has a variable funding cost of about 10.35%.
That balance sheet explains why the FY26 covenant risk remains relevant even after the company returned to positive operating cash flow. Atomos reported only A$196,000 of unused financing facilities at quarter-end, leaving limited room for a prolonged period of weak sales or further working-capital pressure.
Q2 carries the next test of the turnaround
Atomos describes Q2 as historically its strongest trading quarter and expects new product launches, Shinobi 7 II backlog and Flanders reference monitors to provide support. It also acknowledged subdued trading conditions, inflationary pressure in the United States and temporary supply constraints, while saying inventory and working capital are being watched closely.
The board is also seeking approval for a 20-for-1 share consolidation, intended to reduce the number of shares on issue and improve price granularity without changing shareholders’ proportional ownership, apart from fractional-entitlement adjustments. Simon Traynor has joined as a non-executive director, while co-founder Jeromy Young is due to retire after the November annual meeting. The immediate financial question is less whether Atomos can produce a positive quarter than whether Q2 sales arrive strongly enough, and consistently enough, to support the debt burden once the receivables boost fades.
Bottom Line?
Q2 must turn Shinobi 7 II demand and the expanded Flanders range into cash sales while Atomos operates with limited liquidity and substantial debt.
Questions in the middle?
- Can Atomos convert Shinobi 7 II’s reported backlog into revenue while component shortages persist?
- Will the seasonal Q2 uplift be sufficient to improve liquidity and support debt servicing?
- How quickly can Flanders Scientific’s expanded product range contribute beyond its initial in-line quarter?